The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Allosteric inhibitors of Bcr-abl–dependent cell proliferation
Open accessOverview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Chou, T.-C., & Talalay, P. (1984) · Advances in Enzyme Regulation · doi:10.1016/0065-2571(84)90007-4 · Cited by 7,178
Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification
Gorre, M. E., Mohammed, M., Ellwood, K., Hsu, N., Paquette, R., Rao, P. N., & Sawyers, C. L. (2001) · Science · doi:10.1126/science.1062538 · Cited by 3,104
Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells
Druker, B. J., Tamura, S., Buchdunger, E., Ohno, S., Segal, G. M., Fanning, S., Zimmermann, J., & Lydon, N. B. (1996) · Nature Medicine · doi:10.1038/nm0596-561 · Cited by 2,967
Overriding Imatinib Resistance with a Novel ABL Kinase Inhibitor
Shah, N. P., Tran, C., Lee, F. Y., Chen, P., Norris, D., & Sawyers, C. L. (2004) · Science · doi:10.1126/science.1099480 · Cited by 1,796
Structural Mechanism for STI-571 Inhibition of Abelson Tyrosine Kinase
Schindler, T., Bornmann, W., Pellicena, P., Miller, W. T., Clarkson, B., & Kuriyan, J. (2000) · Science · doi:10.1126/science.289.5486.1938 · Cited by 1,780
The Conformational Plasticity of Protein Kinases
Huse, M., & Kuriyan, J. (2002) · Cell · doi:10.1016/s0092-8674(02)00741-9 · Cited by 1,752
Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl
Weisberg, E., Manley, P. W., Breitenstein, W., Brüggen, J., Cowan-Jacob, S. W., Ray, A., Huntly, B., Fabbro, D., Fendrich, G., Hall-Meyers, E., et al. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.01.007 · Cited by 1,492
Self-citationGlivec (STI571, imatinib), a rationally developed, targeted anticancer drug
Capdeville, R., Buchdunger, E., Zimmermann, J., & Matter, A. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd839 · Cited by 1,389
Meijer, L., Borgne, A., Mulner, O., Chong, J. P. J., Blow, J. J., Inagaki, N., Inagaki, M., Delcros, J., & Moulinoux, J. (1997) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1997.t01-2-00527.x · Cited by 1,352
Buchdunger, E., Zimmermann, J., Mett, H., Meyer, T., Müller, M., Druker, B. J., & Lydon, N. (1996) · PubMed · Cited by 1,057
Chronic Myeloid Leukemia — Advances in Biology and New Approaches to Treatment
Goldman, J. M., & Melo, J. V. (2003) · New England Journal of Medicine · doi:10.1056/nejmra020777 · Cited by 950
Structural Basis for the Autoinhibition of c-Abl Tyrosine Kinase
Nagar, B., Hantschel, O., Young, M. A., Scheffzek, K., Veach, D., Bornmann, W., Clarkson, B., Superti-Furga, G., & Kuriyan, J. (2003) · Cell · doi:10.1016/s0092-8674(03)00194-6 · Cited by 879
Branford, S., Rudzki, Z., Walsh, S., Parkinson, I., Grigg, A., Szer, J., Taylor, K., Herrmann, R., Seymour, J. F., Arthur, C., et al. (2003) · Blood · doi:10.1182/blood-2002-09-2896 · Cited by 765
Ohren, J. F., Chen, H., Pavlovsky, A., Whitehead, C., Zhang, E., Kuffa, P., Yan, C., McConnell, P., Spessard, C., Banotai, C., et al. (2004) · Nature Structural & Molecular Biology · doi:10.1038/nsmb859 · Cited by 626
Barker, A. J., Gibson, K. H., Grundy, W., Godfrey, A. A., Barlow, J. J., Healy, M. P., Woodburn, J. R., Ashton, S. E., Curry, B. J., Scarlett, L., et al. (2001) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(01)00344-4 · Cited by 569
Carroll, M., Ohno-Jones, S., Tamura, S., Buchdunger, E., Zimmermann, J., Lydon, N. B., Gilliland, D. G., & Druker, B. J. (1997) · Blood · doi:10.1182/blood.v90.12.4947 · Cited by 554
Burke, J. R., Pattoli, M. A., Gregor, K. R., Brassil, P. J., MacMaster, J. F., McIntyre, K. W., Yang, X., Iotzova, V. S., Clarke, W., Strnad, J., et al. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m209677200 · Cited by 550
Allosteric Activators of Glucokinase: Potential Role in Diabetes Therapy
Grimsby, J., Sarabu, R., Corbett, W. L., Haynes, N.-E., Bizzarro, F. T., Coffey, J. W., Guertin, K. R., Hilliard, D. W., Kester, R. F., Mahaney, P. E., et al. (2003) · Science · doi:10.1126/science.1084073 · Cited by 526
A Myristoyl/Phosphotyrosine Switch Regulates c-Abl
Hantschel, O., Nagar, B., Guettler, S., Kretzschmar, J., Dorey, K., Kuriyan, J., & Superti-Furga, G. (2003) · Cell · doi:10.1016/s0092-8674(03)00191-0 · Cited by 480
von Bubnoff, N., Schneller, F., Peschel, C., & Duyster, J. (2002) · The Lancet · doi:10.1016/s0140-6736(02)07679-1 · Cited by 464
Discovery of a novel Raf kinase inhibitor.
Lyons, J. F., Wilhelm, S., Hibner, B., & Bollag, G. (2001) · Endocrine-related cancer · doi:10.1677/erc.0.0080219 · Cited by 416
BARNETT, S. F., DEFEO-JONES, D., FU, S., HANCOCK, P. J., HASKELL, K. M., JONES, R. E., KAHANA, J. A., KRAL, A. M., LEANDER, K., LEE, L. L., et al. (2005) · Biochemical Journal · doi:10.1042/bj20041140 · Cited by 396
Pyrazole Urea-Based Inhibitors of p38 MAP Kinase: From Lead Compound to Clinical Candidate
Regan, J., Breitfelder, S., Cirillo, P., Gilmore, T., Graham, A. G., Hickey, E., Klaus, B., Madwed, J., Moriak, M., Moss, N., et al. (2002) · Journal of Medicinal Chemistry · doi:10.1021/jm020057r · Cited by 348
A non-ATP-competitive inhibitor of BCR-ABL overrides imatinib resistance
Gumireddy, K., Baker, S. J., Cosenza, S. C., John, P., Kang, A. D., Robell, K. A., Reddy, M. V. R., & Reddy, E. P. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0408283102 · Cited by 220
Structure‐function relationships in Src family and related protein tyrosine kinases
Superti‐Furga, G., & Courtneidge, S. A. (1995) · BioEssays · doi:10.1002/bies.950170408 · Cited by 200
Mechanisms and implications of imatinib resistance mutations in BCR-ABL
Nardi, V., Azam, M., & Daley, G. Q. (2004) · Current Opinion in Hematology · doi:10.1097/00062752-200401000-00006 · Cited by 191
Activation of Src kinases p53/56lyn and p59hck by p210bcr/abl in myeloid cells.
Danhauser-riedl, S., Warmuth, M., Druker, B. J., Emmerich, B., & Hallek, M. J. (1996) · PubMed · Cited by 182
Topaly, J., Zeller, W., & Fruehauf, S. (2001) · Leukemia · doi:10.1038/sj.leu.2402041 · Cited by 170
A Combinatorial Scaffold Approach toward Kinase-Directed Heterocycle Libraries
Ding, S., Gray, N. S., Wu, X., Ding, Q., & Schultz, P. G. (2002) · Journal of the American Chemical Society · doi:10.1021/ja0170302 · Cited by 167
Self-citationCowan-Jacob, S., Guez, V., Fendrich, G., Griffin, J., Fabbro, D., Furet, P., Liebetanz, J., Mestan, J., & Manley, P. (2004) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/1389557043487321 · Cited by 163
Self-citationDesign and Discovery of Small Molecules Targeting Raf-1 Kinase
Lowinger, T. B., Riedl, B., Dumas, J., & Smith, R. A. (2002) · Current Pharmaceutical Design · doi:10.2174/1381612023393125 · Cited by 150
Phosphatidylinositol-3 kinase inhibitors enhance the anti-leukemia effect of STI571
Klejman, A., Rushen, L., Morrione, A., Słupianek, A., & Skórski, T. (2002) · Oncogene · doi:10.1038/sj.onc.1205724 · Cited by 150
Sun, X., Layton, J. E., Elefanty, A. G., & Lieschke, G. J. (2001) · Blood · doi:10.1182/blood.v97.7.2008 · Cited by 77
von Bubnoff, N. C. C., Veach, D. R., Miller, W. T., Li, W., Sänger, J., Peschel, C., Bornmann, W. G., Clarkson, B., & Duyster, J. (2003) · PubMed · Cited by 66
Cited by
Kinase-targeted cancer therapies: progress, challenges and future directions
Bhullar, K. S., Lagarón, N. O., McGowan, E. M., Parmar, I., Jha, A., Hubbard, B. P., & Rupasinghe, H. P. V. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0804-2 · Cited by 1,245
Roskoski, R. (2016) · Pharmacological Research · doi:10.1016/j.phrs.2015.10.021 · Cited by 886
Quantitative Analysis of Hsp90-Client Interactions Reveals Principles of Substrate Recognition
Taipale, M., Krykbaeva, I., Koeva, M., Kayatekin, C., Westover, K. D., Karras, G. I., & Lindquist, S. (2012) · Cell · doi:10.1016/j.cell.2012.06.047 · Cited by 879
Kenakin, T., & Miller, L. J. (2010) · Pharmacological Reviews · doi:10.1124/pr.108.000992 · Cited by 573
Studying clonal dynamics in response to cancer therapy using high-complexity barcoding
Bhang, H.-E. C., Ruddy, D. A., Krishnamurthy Radhakrishna, V., Caushi, J. X., Zhao, R., Hims, M. M., Singh, A. P., Kao, I., Rakiec, D., Shaw, P., et al. (2015) · Nature Medicine · doi:10.1038/nm.3841 · Cited by 507
Metadata
- Authors
- Adrián, F. J., Ding, Q., Sim, T., Velentza, A., Sloan, C., Liu, Y., Zhang, G., Hur, W., Ding, S., Manley, P., Mestan, J., Fabbro, D., & Gray, N. S.
- Venue
- Nature Chemical Biology
- Published
- 2006-01-15
- Volume
- 2
- Issue
- 2
- Pages
- 95-102
- ISSN
- 1552-4450 (ISSN-L)
- 1552-4469
- OpenAlex
- W1980590401
- Cited by
- 381
- References
- 34
- FWCI
- 10.63
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.